This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in South Carolina
Licensed South Carolina practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. South Carolina buyers need their own professional license and NPI; the wholesale distributor permit is the supplier’s obligation, not the purchaser’s.
South Carolina is a state where it pays to check citations. A Nonembryonic and Nonfetal Cell Therapy Act passed the House unanimously in 2014 and still circulates in secondary sources, but it died in the Senate and was never codified. The statute the state did enact, the Right to Try Act, covers terminal illness and investigational products, which is a different subject entirely.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Carolina del Sur? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Carolina del Sur
ExaVeyra ships to licensed practices in all 50 states, South Carolina included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active South Carolina professional license in good standing, verifiable through LLR’s online licensee lookup.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A South Carolina resale certificate through the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
South Carolina permits facilities engaged in the sale and distribution of prescription drugs and devices through the Board of Pharmacy, within the Department of Labor, Licensing and Regulation, and issues a Non-Resident Wholesale Distributor Permit to wholesalers, distributors, manufacturers, and repackagers of legend drugs or devices shipping in from out of state. Two features stand out. Board Policy 145 requires nonresident wholesale distributors to hold NABP Drug Distributor Accreditation or meet its standards, which most states do not require. And controlled substances take a separate registration with the Bureau of Drug Control, now housed in the Department of Public Health after the 2024 DHEC restructuring. The permit sits with the distributor, not with the purchasing practice.
S.C. Code Ann. 40-43-83, 40-43-30(60); S.C. Code Regs. ch. 99 · South Carolina Board of Pharmacy (Department of Labor, Licensing and Regulation)
Carolina del Sur regenerative-medicine law
Carolina del Sur has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
South Carolina has enacted no statute addressing unapproved regenerative therapy, and its legislative history is the interesting part. H 3764, the Nonembryonic and Nonfetal Cell Therapy Act, would have authorized nonembryonic cell and tissue banks and limited state regulation of them; it passed the House 107 to 0 in January 2014 and died in the Senate Medical Affairs Committee, so Title 44 Chapter 43 contains no such article today. The Right to Try Act, enacted in 2016 as Act 230 and codified at S.C. Code 44-137, is sometimes cited in its place, but it reaches only patients with a terminal illness using investigational products that have completed a phase 1 clinical trial, under physician recommendation and written informed consent. Practice outside that narrow lane is governed by the Medical Practice Act, the Nurse Practice Act, and the boards that administer them, alongside federal law.
How this applies to exosomes
South Carolina has no stem cell or cell therapy statute: the bill that would have created one died in the Senate in 2014, and the Right to Try Act that did pass is confined to terminal illness and investigational products that have completed phase 1, which is not a regenerative medicine framework. There is therefore no South Carolina definition that reaches exosomes, which are acellular extracellular vesicles, either to permit or to restrict. Exosome products in South Carolina are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Carolina del Sur practice
South Carolina is a practice agreement state. Nurse practitioners and physician assistants each work under written agreements with a physician, the physician must be readily available for consultation rather than on site, and one physician may cover the equivalent of up to six full-time advanced practice providers across both professions. The examination rule in S.C. Code 40-47-113 is the piece aesthetic practices most often plan around, because it requires an appropriate history and physical examination before prescribing, and it names the APRN and PA pathway as the route by which an extender’s examination can support the supervising physician’s prescribing.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Board of Medical Examiners perform medical acts within their scope and are the source of any delegation. Under S.C. Code 40-47-113 a licensee establishes a physician-patient relationship by personally performing and documenting an appropriate history and physical examination, making a diagnosis, and formulating the plan before prescribing, with stated exceptions that include patients examined by an APRN or PA the physician supervises. |
| NP / APRN | South Carolina nurse practitioners perform medical acts under a written practice agreement with a physician under S.C. Code 40-33-34. The physician must hold an active unrestricted South Carolina license and be readily available for consultation, in person or by telecommunications, and prescriptive authority, including scheduled drug limits, is defined in the agreement. One physician may work with the equivalent of up to six full-time advanced practice providers. |
| PA | Physician assistants practice under scope of practice guidelines with a supervising physician under Article 7 of the Medical Practice Act, S.C. Code Chapter 40-47, within the scope the supervising physician delegates, and count toward the same six-provider equivalence limit as APRNs. |
| RN | Registered nurses carry out treatments on the order of an authorized provider within the Nurse Practice Act, S.C. Code Chapter 40-33. Delegation downward is tightly bounded: under S.C. Code 40-33-42 unlicensed assistive personnel may take only routine tasks and must not administer medications except as otherwise provided by law. |
Good faith examination
South Carolina codifies the expectation most states leave to board guidance: S.C. Code 40-47-113 makes it unprofessional conduct to prescribe based solely on answers to questions, and requires a documented history and physical examination, a diagnosis, and a therapeutic plan to establish the physician-patient relationship, with exceptions that include examination by a supervised APRN or PA and telemedicine compliant with the telemedicine statute.
Ownership and clinic licensing
South Carolina’s corporate practice of medicine position rests on the Medical Practice Act and Attorney General opinions rather than a codified prohibition, and professional entities with management services arrangements are the usual structures. Because the position is not set out as a bright-line statutory rule, published summaries disagree with one another, and ownership structure here is a question for South Carolina counsel and the Board of Medical Examiners rather than one a guide should answer with a percentage.
Cold chain into Carolina del Sur
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Carolina del Sur order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Charleston | Charleston | Largest coastal market, with deep aesthetic and concierge coverage. |
| Mount Pleasant | Charleston | Affluent east-of-the-Cooper corridor served alongside Charleston. |
| Columbia | Richland | Capital market with a university medical presence. |
| Greenville | Greenville | Fast-growing Upstate market on the Charlotte-Atlanta corridor. |
| Hilton Head Island | Beaufort | Lowcountry resort market with seasonal demand. |
| Myrtle Beach | Horry | Grand Strand market with a growing med spa segment. |
- South Carolina orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Wholesale exosome supply by city in Carolina del Sur
Each city page covers local receiving conditions, delivery disruptions and business license rules for Carolina del Sur practices in that area.
Practice types we supply in Carolina del Sur
Carolina del Sur licensing and verification
South Carolina Board of Medical Examiners (LLR)
Licenses physicians and physician assistants.
South Carolina Board of Nursing (LLR)
Licenses APRNs, who practice under written practice agreements.
South Carolina Board of Pharmacy (LLR)
Issues the Non-Resident Wholesale Distributor Permit.
South Carolina Department of Public Health, Bureau of Drug Control
Controlled substances registration, moved from DHEC in the 2024 restructuring.
South Carolina Department of Revenue
Sales and use tax registration and resale certificates.
Carolina del Sur sourcing questions
- Does South Carolina have a stem cell law?
- No. The Nonembryonic and Nonfetal Cell Therapy Act, H 3764, passed the House 107 to 0 in January 2014 and died in the Senate Medical Affairs Committee, so it was never codified. The Right to Try Act the state did enact in 2016 covers terminal illness and investigational products that have completed phase 1, which is a different subject. Exosome products in South Carolina are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- Does the South Carolina Right to Try Act cover regenerative products?
- Only in the narrow lane the statute defines. S.C. Code 44-137 reaches patients with a terminal illness, using an investigational drug, biological product, or device that has completed a phase 1 clinical trial, on a treating physician’s recommendation with written informed consent. It is not a regenerative medicine framework and does not change how products are regulated outside that setting.
- Does my South Carolina clinic need a wholesale permit to buy exosomes?
- No. The Non-Resident Wholesale Distributor Permit under S.C. Code 40-43-83 is held by the distributor shipping into South Carolina, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- What does a South Carolina nurse practitioner need in place?
- A written practice agreement with a physician under S.C. Code 40-33-34, defining the medical acts covered and the prescriptive authority, including scheduled drug limits. The physician must hold an active unrestricted South Carolina license and be readily available for consultation, though not on site, and one physician may work with the equivalent of up to six full-time advanced practice providers.
- What examination does South Carolina require before treatment?
- S.C. Code 40-47-113 requires a licensee to establish the physician-patient relationship by personally performing and documenting an appropriate history and physical examination, making a diagnosis, and formulating a therapeutic plan before prescribing, and makes prescribing on answers to a questionnaire alone unprofessional conduct. The stated exceptions include a patient examined by an APRN or PA the physician supervises, and telemedicine compliant with the telemedicine statute.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification about exosome products marketed outside that framework. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to South Carolina?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- South Carolina Board of Pharmacy, permits and registration requirements (accessed 16 October 2026)
- S.C. Code Chapter 40-43, Pharmacy Practice Act, including 40-43-83 on facility permits (accessed 16 October 2026)
- S.C. Code Chapter 44-137, Right to Try Act (accessed 16 October 2026)
- South Carolina General Assembly, H 3764 (2013-2014), Nonembryonic and Nonfetal Cell Therapy Act, bill history (accessed 16 October 2026)
- S.C. Code Chapter 40-33, Nurse Practice Act (accessed 16 October 2026)
- South Carolina Department of Public Health, Bureau of Drug Control (accessed 16 October 2026)
- South Carolina Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The field’s current characterization standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page says accompanies every South Carolina shipment.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: Sets out what an MSC-derived small EV preparation must demonstrate, supporting this page’s description of perinatal MSC-derived exosome source material and its documentation standard.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products in trials, which frames this page’s statement that no exosome product is FDA approved.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.